GlassScriptPhysician profile
Majd Chahin
NPI 1760472849
$11,068.30
in general payments reported to CMS, 2019-2025
64 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,467 · 2020: $578 · 2021: $1,028 · 2022: $1,634 · 2023: $2,328 · 2024: $2,910 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735 · Consulting Fee: $400 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,735.09 |
| Consulting Fee | $400.00 |
| Education | $224.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $993.84 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $908.39 | 2019-2024 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $672.80 | 2019-2024 | Opdivo, Opdualag, Augtyro |
| Incyte Corporation | $540.38 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| Beigene, LTD. | $525.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $488.34 | 2019-2024 | Alunbrig, Iclusig, Fruzaqla |
| Celgene Corporation | $471.60 | 2019-2024 | Reblozyl, Pomalyst |
| Pfizer INC. | $471.34 | 2019-2024 | |
| Amgen INC. | $466.79 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
| Lilly USA, LLC | $417.48 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $392.18 | 2019-2024 | Phesgo, Alecensa, Avastin |
| Novartis Pharmaceuticals Corporation | $375.71 | 2019-2024 | |
| Janssen Biotech, INC. | $324.16 | 2019-2024 | Tecvayli, Rybrevant, Talvey |
| Seagen INC. | $295.88 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Genzyme Corporation | $244.44 | 2019-2024 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $240.97 | 2019-2024 | |
| Taiho Oncology, INC. | $237.17 | 2019-2024 | |
| Daiichi Sankyo INC. | $192.59 | 2021-2024 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $177.54 | 2019-2024 | |
| Gilead Sciences, INC. | $169.36 | 2021-2024 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $162.92 | 2022-2024 | Libtayo |
| Novocure INC. | $145.62 | 2023-2024 | Optune Lua (Novottf-200t), Optune |
| Astellas Pharma US INC | $139.41 | 2019-2023 | Xospata |
| Puma Biotechnology, INC. | $121.79 | 2019-2024 | |
| Exelixis INC. | $97.01 | 2020-2023 | Cabometyx |
| Kyowa Kirin, INC. | $96.58 | 2019 | |
| Jazz Pharmaceuticals INC. | $94.98 | 2019-2024 | Zepzelca |
| Glaxosmithkline, LLC. | $93.53 | 2022-2024 | Jemperli, Zejula, Shingrix |
| Abbvie INC. | $93.22 | 2022-2024 | Venclexta |
| Sobi, INC | $91.69 | 2023-2024 | |
| Acrotech Biopharma INC. | $90.78 | 2022-2023 | Beleodaq |
| Pharmacyclics LLC, An Abbvie Company | $81.24 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $70.68 | 2023-2024 | Qinlock |
| Ipsen Biopharmaceuticals, INC | $69.72 | 2019-2024 | Onivyde, Somatuline Depot |
| Adaptive Biotechnologies Corporation | $68.70 | 2022-2024 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $68.08 | 2020-2024 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $64.85 | 2022-2023 | Fotivda |
| Karyopharm Therapeutics INC. | $60.42 | 2023-2024 | Xpovio |
| Beigene USA, INC. | $59.81 | 2023-2024 | Brukinsa |
| Cti Biopharma Corp. | $51.55 | 2022-2023 | Vonjo |
| Array Biopharma INC | $47.95 | 2023-2024 | Braftovi, Lorbrena, Mektovi |
| Genmab U.S., INC. | $47.65 | 2023-2024 | Tivdak, Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.36 | 2019-2021 | |
| Servier Pharmaceuticals LLC | $44.43 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $41.83 | 2019-2024 | Tavalisse, Rezlidhia |
| Tempus Ai, INC | $38.16 | 2024 | Xt Cdx |
| Mirati Therapeutics, INC. | $35.38 | 2023 | Krazati |
| Amag Pharmaceuticals, INC. | $33.96 | 2019 | |
| Pharmaessentia USA Corporation | $33.34 | 2022-2024 | Besremi |
| Adc Therapeutics America, INC. | $30.70 | 2022-2024 | |
| Octapharma USA, INC. | $24.57 | 2023 | Octagam Immune Globulin (Human) |
| G1 Therapeutics, INC. | $23.26 | 2023 | Cosela |
| Kite Pharma, INC. | $22.01 | 2025 | Yescarta |
| Springworks Therapeutics, INC. | $20.79 | 2024 | Ogsiveo |
| Coherus Oncology, INC. | $20.26 | 2020 | |
| Blue Earth Diagnostics | $18.51 | 2023 | |
| Myriad Genetic Laboratories, INC. | $16.51 | 2023 | Precisetumor |
| Immunogen, INC. | $15.35 | 2023 | Elahere |
| Recordati_rare_diseases_inc. | $15.00 | 2023 | Sylvant |
| Morphosys, US INC. | $13.14 | 2024 | Monjuvi |
| Teva Pharmaceuticals USA, INC. | $12.96 | 2019 | |
| Mylan Institutional INC. | $12.89 | 2021 | |
| Eusa Pharma (US) LLC | $12.56 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majd Chahin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.